Aptose Biosciences
Corporate Headquarters
251 Consumers Road
Suite 1105
Toronto
Ontario
M2J 4R3
Canada
Website: http://aptose.com/
178 articles about Aptose Biosciences
-
Aptose Reports Results for the First Quarter 2021
5/4/2021
Aptose Biosciences Inc., a clinical-stage company developing highly differentiated agents that target the underlying mechanisms of cancer, announced financial results for the three months ended March 31, 2021 and provided a corporate update.
-
Aptose to Report First Quarter 2021 Financial Results and Hold Conference Call on Tuesday, May 4, 2021
4/26/2021
Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, will report financial results for the quarter ended March 31, 2021, and provide a corporate update on Tuesday, May 4, 2021, after the close of the market. Conference Call & Webcast: Date: Tuesday, May 4, 2021 Time: 4:30 PM ET
-
Aptose to Present at Canaccord Genuity 2021 Horizons in Oncology Virtual Conference
4/8/2021
Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, will participate in Canaccord Genuity’s 2021 Horizons in Oncology Virtual Conference
-
Aptose Reports Results for the Fourth Quarter and Full Year 2020
3/23/2021
Aptose Biosciences Inc., a clinical-stage company developing highly differentiated agents that target the underlying mechanisms of cancer, announced financial results for the year and three months ended December 31, 2020 and a corporate update.
-
Aptose Expands Senior Leadership Team
3/16/2021
Aptose Biosciences Inc. announced the appointment of two key members to its management team to support the company’s expanding clinical CMC and regulatory functions: George P. Melko, Pharm.D., joins Aptose as Vice President, Regulatory Affairs; and Robert B. Killion Jr., Ph.D. has been named Vice President, CMC.
-
Aptose to Release Fourth Quarter and Year End December 31, 2020 Financial Results and Hold Conference Call on March 23, 2021
3/2/2021
Aptose Biosciences Inc., a clinical stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, will release its financial results for the year and quarter ended December 31, 2020, on Tuesday, March 23, 2021 after the close of the market.
-
Aptose Presents Highlights from ASH and Corporate Update Event
12/6/2020
Aptose Biosciences Inc. released highlights from a corporate update event held on Sunday, December 6th, in conjunction with participation at the 2020 American Society of Hematology Annual Meeting.
-
Aptose to Hold Corporate Update Sunday, December 6th
12/1/2020
Poster Presentations for CG-806 and APTO-253 are scheduled for December 5th and 6th at 2020 ASH Annual Meeting and Exposition
-
Aptose Reports Results for the Third Quarter 2020
11/10/2020
Aptose Biosciences Inc., a clinical-stage company developing highly differentiated agents that target the underlying mechanisms of cancer, announced financial results and a corporate update for the three months ended September 30, 2020.
-
Aptose to Present CG-806 and APTO-253 Data at the 2020 ASH Annual Meeting Abstracts Accepted for Presentation
11/4/2020
Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that early clinical data, along with certain preclinical data, for CG-806, an oral, first-in-class FLT3 and BTK cluster selective kinase inhibitor, and early clinical data for APTO-253, a first-in-class small molecule MYC inhibitor, will be prese
-
Aptose to Release Third Quarter Ended September 30, 2020 Financial Results and Hold Conference Call on November 10, 2020
10/27/2020
Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, will release its financial results for the quarter ended September 30, 2020 on Tuesday, November 10, 2020, after the close of the market.
-
Aptose Initiates Dosing of CG-806 in Patients with Acute Myeloid LeukemiaPhase 1 a/b Study of CG-806 in AML Initiates with Starting Dose of 450mg
10/19/2020
Aptose Biosciences Inc. announced dosing of the first patient with acute myeloid leukemia in a Phase 1 a/b clinical study with CG-806, the company’s oral kinase inhibitor that potently inhibits the wildtype and mutant forms of FLT3 and BTK, and suppresses select clusters of kinases that drive oncogenic signaling pathways.
-
Aptose to Present at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
9/15/2020
Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, and the Aptose management team will participate at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit: Oppenheimer Fall Healthcare Life Sciences & Medtech
-
Aptose to Present at September Investor Conferences
9/9/2020
Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, and the Aptose management team will participate at the upcoming conferences in September 2020: H. C. Wainwright 22nd Annual Global Investment Conference Date: Monday,
-
Aptose Biosciences to Present at Canaccord Genuity 40th Annual Growth Conference
8/6/2020
Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that William G. Rice, Chairman, Ph.D., President and Chief Executive Officer; Gregory K. Chow, Executive Vice President and Chief Financial Officer; and Joti Marango, M.D., Ph.D, Senior Vice President and Chief Business Officer, will participate in the Cana
-
Aptose Reports Results for the Second Quarter 2020
8/4/2020
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated agents that target the underlying mechanisms of cancer, today announced financial results and corporate update for the three months ended June 30, 2020.
-
Aptose to Release Second Quarter Ended June 30, 2020 Financial Results and Hold Conference Call on August 4, 2020
7/21/2020
Aptose Biosciences Inc., a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, will release its financial results for the quarter ended June 30, 2020, on Tuesday, August 4, 2020, after the close of the market.
-
Aptose Announces Pricing of Public Offering of Common Shares - July 16, 2020
7/16/2020
Aptose Biosciences Inc., announced that it priced its previously announced underwritten public offering of 10,500,000 common shares at a public offering price of US$5.25 per share.
-
Aptose Announces Proposed Public Offering of Common Shares - July 15, 2020
7/15/2020
Aptose Biosciences Inc. announced that it has commenced an underwritten public offering of its common shares.
-
Clinical Catch-Up: June 29-July 3
7/6/2020
Heading into the 4th of July holiday in the U.S., there was still a fair amount of clinical trial news last week. Here’s a look.